CLINICIANS IN ODENSE, DENMARK, FIRST IN SCANDINAVIA TO OFFER NEW INNOVATIVE TECHNOLOGY FROM ELEKTA FOR FASTER AND MORE ACCURATE CANCER TREATMENT

CLINICIANS IN ODENSE, DENMARK, FIRST IN SCANDINAVIA TO OFFER NEW INNOVATIVE
TECHNOLOGY FROM ELEKTA FOR FASTER AND MORE ACCURATE CANCER TREATMENT

Press Release 
Stockholm, Sweden, September 21, 2008

Odense University Hospital in Denmark has become the first Scandinavian cancer
centre to choose Elekta VMAT (Volumetric intensity Modulated Arc Therapy) to
expand the capabilities of the hospital's radiation oncology department. The
addition of this solution to the range of treatment techniques will provide
physicians with the ability to treat cancer tumors with improved precision and
accuracy, while at the same time significantly reduce treatment times.


Elekta VMAT has the unique ability to use single or multiple gantry arcs that
sweep non-stop over the target isocenter, while simultaneously optimizing gantry
speed, multileaf collimator leaves, dose rate and collimator angle. It delivers
real-time flexibility in delivering uninterrupted prescriptions, dynamic leakage
reduction and the flexibility to perform one or more multiple treatment arcs -
the only clinically available VMAT solution able to do so.

From the patient's perspective, Elekta VMAT combines a significant reduction in
treatment time with optimal avoidance of radiation dose to healthy tissues
surrounding the tumor. From the clinician's perspective, the reduction in
treatment time makes it much easier to accurately target the tumor and the
improved dose sparing offers new options to either increase dose to tumor or
reduce side effects and therefore potentially improve outcomes. For the clinic
administrator, reduced treatment times and the opportunity to increase dose and
reduce the number of treatment sessions increases the number of patients that
can be treated using their existing equipment.

“Elekta VMAT is unique in allowing us to optimize all parameters of treatment
delivery in order to maximize dose to the tumor whilst minimizing unwanted
radiation to healthy tissue” explains Knud Aage Werenberg, Head Physicist,
Odense University Hospital. “An added benefit of this new technology is that it
dramatically reduces both treatment times and radiation dose, allowing us to
treat more patients and minimize unwanted side effects,” he continues.

Odense University Hospital already provide the world leading image guided
radiation therapy (IGRT) with Elekta Synergy®, improving treatment accuracy by
allowing physicians to precisely target tumors using 3D pre-treatment imaging.
Elekta VMAT will prove the next step towards establishing their reputation as a
world class center of excellence. 

“We are very happy to see Elekta VMAT being quickly implemented in one of
Scandinavia's leading hospitals,” remarked Olof Sandén, Executive Vice President
Region Europe at Elekta. “We are proud of a product development which gives
physicians the ability to fully utilize the freedom of the equipment and
optimize each of the treatment variables, thereby delivering the treatment which
best suits each patients' needs,” he adds.

Odense University Hospital now joins the many European, American and Asian
leading cancer treatment centers that now are using Elekta VMAT to treat
patients, several of which have or will present data at this year's ESTRO and
ASTRO annual meetings.



For further information, please contact:

Media: 
Florian Meinel, Marketing Director, Elekta Europe
Tel: +49 1728971838, florian.meinel@elekta.com

Inverstors:
Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com  


About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.